Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2011

GenVec and NMRC Take On Dengue Fever Vaccine R&D

  • GenVec and the U.S. Naval Medical Research Center (NMRC) have entered into a CRADA to support NMRC’s dengue fever vaccine research. Under a separate contract with the Henry M. Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to this program.

    The company anticipates that it will recognize approximately $530,000 of revenue associated with the completion of work under the agreement with the Jackson Foundation, which is expected this year.

    GenVec will be responsible for designing and manufacturing candidates using its adenovector technology. The vaccines will be manufactured utilizing GenVec's cell line. NMRC will be responsible for preclinical animal studies including studies in nonhuman primates.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »